Vertex Story

VRTX -- USA Stock

USD 212.06 1.68 0.80%

Macroaxis Story

Vertex Pharmaceuticals is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 1st of February 2021. Vertex Pharmaceuticals Interest Coverage is fairly stable at the moment as compared to the past year. Vertex Pharmaceuticals reported Interest Coverage of 16.75 in 2020. Calculated Tax Rate is likely to rise to 19.40 in 2021, whereas Earnings before Tax are likely to drop (118.4 M) in 2021. Although many aggressive traders are getting into healthcare space, Vertex Pharmaceuticals Incorpor may or may not be your first choice. What exactly are Vertex Pharmaceuticals shareholders getting in March?

Published over three weeks ago

View all stories for Vertex Pharmaceutic | View All Stories

How much will Vertex Pharmaceuticals owe in March?

Vertex Pharmaceuticals currently holds 546.51 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest Vertex Pharmaceuticals is not taking enough advantage from borrowing. The entity has a current ratio of 3.65, suggesting that it is liquid enough and is able to pay its financial obligations when due. About 96.0% of the company outstanding shares are owned by institutional investors. Vertex Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.9. The entity recorded earning per share (EPS) of 10.2. The firm had not issued any dividends in recent years. Vertex Pharmaceuticals had 2:1 split on the 24th of August 2000.

Vertex Pharmaceutic financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Vertex Pharmaceutic, including all of Vertex Pharmaceutic's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Vertex Pharmaceutic assets, the company is considered highly leveraged. Understanding the composition and structure of overall Vertex Pharmaceutic debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.

Please read more on our technical analysis page.

Understanding Vertex Total Debt

Vertex Pharmaceutic liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Vertex Pharmaceutic has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Vertex Pharmaceutic balance sheet include debt obligations and money owed to different Vertex Pharmaceutic vendors, workers, and loan providers. Below is the chart of Vertex main long-term debt accounts currently reported on its balance sheet.

You can use Vertex Pharmaceutic financial leverage analysis tool to get a better grip on understanding its financial position

How important is Vertex Pharmaceutic's Liquidity

Vertex Pharmaceutic financial leverage refers to using borrowed capital as a funding source to finance Vertex Pharmaceutic ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Vertex Pharmaceutic financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Vertex Pharmaceutic's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.

It is good to see analyst projects for Vertex Pharmaceutic, but it might be worth checking our own buy vs. sell analysis

Payment of 311 shares by Bozic Carmen of Vertex Pharmaceutic subject to Rule 16b-3

Legal trades by Vertex Pharmaceutic insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Vertex insider trading alert for payment of common stock by Bozic Carmen, EVP and CMO, on 26th of February 2021. This event was filed by Vertex Pharmaceuticals In with SEC on 2021-02-26. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Vertex Pharmaceutic Investor Appetite?

The firm reported the previous year's revenue of 5.99 B. Net Income was 2.69 B with profit before overhead, payroll, taxes, and interest of 1.86 B.

Liabilities Breakdown

1.3 B

Current Liabilities

596.3 M

Long-Term Liabilities

	Deposit Liabilities	65.69 Million
	Total Liabilities	1.71 Billion
	Current Liabilities	1.3 Billion
	Long-Term Liabilities	596.27 Million
	Tax Liabilities	10.8 Million

Vertex Pharmaceuticals is epected to finish above $225 in March

Current Risk Adjusted Performance is up to 0.1. Price may slide again. Vertex Pharmaceuticals Incorpor has relatively low volatility with skewness of -0.47 and kurtosis of 0.88. However, we advise all investors to independently investigate Vertex Pharmaceuticals Incorpor to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Final Take On Vertex Pharmaceuticals

While other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Vertex Pharmaceuticals may offer a potential longer-term growth to investors. To conclude, as of the 31st of January 2021, our concluding 30 days buy-or-sell advice on the company is Buy. We believe Vertex Pharmaceuticals is undervalued with very small probability of distress for the next two years.

About Contributor

Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Vertex Pharmaceutic. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC